MedTrace Logo

Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia

NCT02445352 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 379

Last updated 2015-05-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate efficacy and safety of DP-R207 in patients with primary hypercholesterolemia.

Conditions

  • Primary Hypercholesterolemia

Interventions

DRUG

Rosuvastatin 5mg

DRUG

DP-R207 5/10mg

DRUG

Rosuvastatin 10mg

DRUG

DP-R207 10/10mg

DRUG

Rosuvastatin 20mg

DRUG

DP-R207 20/10mg

DRUG

Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)

DRUG

Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)

DRUG

Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)

Sponsors & Collaborators

  • Alvogen Korea

    lead INDUSTRY

Principal Investigators

  • Yangsoo Jang, Ph.D. · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-01-31
Completion
2015-03-31

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02445352 on ClinicalTrials.gov